At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 43 enrolled
Drug / intervention
levofloxacin +1 moredrug
Likely dose
levofloxacin 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Fluoroquinolones on BK Viremia in the Renal Transplant Recipient, A Multi-Center Study
In Brief
A Phase 4 clinical trial evaluating levofloxacin and placebo for BK Viremia. Completed, enrolled 43 participants across 8 sites.
Detailed Summary
Our hypothesis is that 30 days of oral levofloxacin (FDA approved antibiotic) in patients with persistent viremia (BK virus found in blood) will impair progress to BK virus induced kidney damage by significantly decreasing or eliminating BK virus in the blood.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBK Viremia
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedDec 2009
Primary CompletionJun 2012
Study CompletionOct 2012
TodayJul 2026
First PostedDec 17, 2009
Enrollment StartFeb 1, 2009
Primary CompletionJun 1, 2012
Study CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 16.5 years ago
Interventions
levofloxacindrug
500 mg tablet, daily, 30 days
placebodrug
no dose, tablet, daily, 30 days